(Q37808639)

23 August 2017

title

Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE). (English)

1 reference

23 August 2017

0 references

1 reference

R Lindsay

1

1 reference

23 August 2017

language of work or name

English

0 references

publication date

11 November 2010

1 reference

Osteoporosis International

23 August 2017

published in

1 reference

23 August 2017

volume

22

1 reference

23 August 2017

issue

2

1 reference

23 August 2017

page(s)

447-451

1 reference

https://scigraph.springernature.com/pub.10.1007/s00198-010-1440-x

23 August 2017

exact match

0 references

cites work

Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1440-X

The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1440-X

Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1440-X

Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1440-X

Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1440-X

Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1440-X

Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1440-X

Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1440-X

Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1440-X

Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1440-X

Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1440-X

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1440-X

Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1440-X

Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. The Menopause Study Group.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21069294

12 December 2020

inferred from PubMed ID database lookup

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21069294

12 December 2020

inferred from PubMed ID database lookup

A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21069294

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S00198-010-1440-X

1 reference

release_odvsfsocfbcq7bj5nft2ofl3oi

23 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/odvsfsocfbcq7bj5nft2ofl3oi

24 November 2022

mapped directly with Wikidata item

1 reference